Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial

Participants were randomized to receive xanthohumol or placebo, with assessments every 2 weeks to evaluate clinical safety, tolerability, and biomarkers related to inflammation and gut health.

Healthy adults were administered either 24 mg/day of xanthohumol or a placebo for 8 weeks in a phase I, triple-masked, randomized, placebo-controlled clinical trial.

The trial aims to establish the safety and tolerability of xanthohumol in healthy adults, with potential implications for future studies in chronic diseases like Crohn's disease.

The evaluation only involves a single dosage of xanthohumol over 8 weeks, which may not be sufficient to assess its full therapeutic potential or toxicity.